The Health Economics of Bladder Cancer: A Comprehensive Review of the Published Literature

PharmacoEconomics

Volumn 21, Issue 18, 2003, Pages 1315-1330

  Botteman, Marc F ^a   Pashos, Chris L ^a   Redaelli, Alberto ^b   Laskin, Benjamin ^a   Hauser, Robert ^a  

^a ABT ASSOCIATES   (United States)

^b Pharmacia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCG VACCINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; MITOMYCIN C; VALRUBICIN; VINBLASTINE;

ADULT; AGED; BLADDER CANCER; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURGERY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYSTECTOMY; CYSTOSCOPY; ECONOMICS; FOLLOW UP; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MASS SCREENING; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URINARY TRACT CANCER;

EID: 0346100499     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03262330     Document Type: Review

References (66)

1. Ferlay J, Bray F, Pisani P, et al., GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Lyon: IARC Press, 2001
2. Miller BA, Kolonel LN, Bernstein L, et al. Racial/ethnic patterns of cancer in the United States 1988-1992. Bethesda (MD): National Cancer Institute; 1996. NIH Pub. No. 96-4104
3. National Cancer Institute. NCI fact book. Bethesda, (MD): National Institutes of Health; 2000. NIH Pub. No. 01-512
4. Marcus PM, Hayes RB, Vineis P, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9 (5): 461-7
5. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13 (5): 291-8
6. Metts MC, Metts JC, Milito SJ, et al. Bladder cancer: a review of diagnosis and management. J Natl Med Assoc 2000; 92 (6): 285-94
7. Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control 2000; 7 (4): 335-9
8. Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 2000; 27 (1): 137-46
9. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000; 27 (1): 1-13, vii
10. Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A (11): 1840-6
11. Young MJ, Soloway MS. Office evaluation and management of bladder neoplasms. Urol Clin North Am 1998; 25 (4): 603-11
12. Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am 2000; 27 (1): 125-35, x
13. Zietman AL, Shipley WU, Kaufman DS. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy. Ann Med 2000; 32 (1): 34-42
14. Brown ML, Fintor L. The economic burden of cancer. In: Greenwald P, Kramer BS, Weed DL, editors. Cancer prevention and control. New York: Marcel-Dekker, 1995: 69-81
15. Salkeld G, Morrell S, Webster F, et al. Economic cost of health, effects of occupational exposure to hazardous substances. Australia: National Occupational Health & Safety Commission, 1996
16. Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33 (8): 828-41
17. Baker S, Kessler LG, Smucker RC. Site-specific treatment costs for cancer: an analysis of the Medicare Continuous History Sample file. In: Scheffler RM, Andrews NC, editors. Cancer care and costs: DRG's and beyond 1989. Ann Arbor (MI): Health Administration Press Perspectives, 1989
18. Abt Associates Inc. Cost of illness handbook. Washington, DC: United States Environmental Protection Agency. Office of Pollution Prevention and Toxics, 2001
19. Ruttenberg R, Powers M. Economics of notification and medical screening for high-risk workers. J Occup Med 1986; 28 (8): 757-64
20. Han M, Schoenberg MP. The use of molecular diagnostics in bladder cancer. Urol Oncol 2000; 5 (3): 87-92
21. Ellwein LB, Farrow GM, Friedell GH, et al. An assessment of the impact of urine cytology screening using a computer-based model of bladder cancer. Urol Clin North Am 1984; 11 (4): 585-98
22. Messing EM, Young TB, Hunt VB, et al. Hematuria home screening: repeat testing results. J Urol 1995; 154 (1): 57-61
23. Brausi M, Ferretti S. Screening for asymptomatic microscopic hematuria (MA) in a health population: results of a study of 2065 individuals [abstract]. J Urol 2000; 163 (4 Suppl.): 3
24. Ellison LM, Ellsworth PI, Birkmeyer JD. Cost-effectiveness of screening for bladder cancer after radiation therapy for prostate cancer [abstract]. J Urol 2000; 163 (4 Suppl.): 3
25. Burchardt M, Burchardt T, Shabsigh A, et al. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000; 46 (5): 595-605
26. Cummings KB, Barone JG, Ward WS. Diagnosis and staging of bladder cancer. Urol Clin North Am 1992; 19 (3): 455-65
27. Corwin HL, Silverstein MD. The diagnosis of neoplasia in patients with asymptomatic microscopic hematuria: a decision analysis. J Urol 1988; 139 (5): 1002-6
28. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999; 161 (1): 62-5
29. Zippe C, Pandrangi L, Potts JM, et al. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res 1999; 19 (4A): 2621-3
30. Hansen MV, Zdanowski A. The agreement among urological experts on the diagnostic management of patients with common urological problems. Br J Urol 1997; 80 (5): 787-92
31. Hunt MT, Woodhouse CR. Cost-effectiveness of investigations for invasive bladder cancer. J R Soc Med 1987; 80 (3): 143-4
32. Lindner A, deKernion JB. Cost-effective analysis of pre-cystectomy radioisotope scans. J Urol 1982; 128 (6): 1181-2
33. Kiemeney LA, Witjes JA, Heijbroek RP, et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150 (1): 60-4
34. Raitanen MP, Tammela TL. Impact of tumour grade, stage, numberand size, smoking habits and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder. Ann Chir Gynaecol 1995; 84 (1): 37-41
35. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164 (3 Pt 1): 680-4
36. Zlotta AR, Schulman CC. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am 2000; 27 (1): 179-xii
37. Kurth KH, Bouffioux C, Sylvester R, et al. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol 2000; 37 Suppl. 3: 1-9
38. Smith Jr JA, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, Tl and TIS): The American Urological Association. J Urol 1999; 162 (5): 1697-701
39. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 2000; 163 (1): 68-71
40. Birch BR, Anson KM, Miller RA. Sedoanalgesia in urology: a safe, cost-effective alternative to general anaesthesia: a review of 1020 cases. Br J Urol 1990; 66 (4): 342-50
41. Holmang S, Aldenborg F, Hedelin H. Multiple bladder biopsies under intravesical lignocaine anaesthesia. Br J Urol 1994; 73 (2): 160-3
42. Hedelin H, Holmang S, Wiman L. Outpatient treatment of bladder cancer: lower cost and satisfied patients. Nord Med 1997; 112 (2): 48-51
43. Jewett MA, Valiquette L, Sampson HA, et al. Electromotive drug administration of lidocaine as an alternative anesthesia for transurethral surgery. J Urol 1999; 161 (2): 482-5
44. Shanberg AM, Marinelli D, Tansey LA, et al. Cost analysis of neodymium-YAG laser versus transurethral resection treatment of superficial bladder carcinoma. Int Surg 1993; 78 (4): 350-1
45. Tellez Martinez-Fornes M, Maganto PE, Vallejo HJ, et al. Treatment of recurrent bladder surface tumors with laser Nd:Yag: a single-year experience. Actas Urol Esp 1993; 17 (1): 35-9
46. Smith PH. The costs of intravesical chemotherapy. Prog Clin Biol Res 1985; 185B: 39-44
47. Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt) 2000; 14 (5): 719-29
48. Carroll PR, Williams RD, Kim MJ, et al. Mitomycin C reused: an in vitro cost-effectiveness study. J Urol 1984; 132 (3): 583-6
49. Kilbridge KL, Kantoff PW, Loughlin KR, et al. Is bacillus calmette-guerin (BCG) immunotherapy cost-effective in recurrent high grade transitional cell cancer (TCC)? [abstract]. J Urol 1997; 157 (4 Suppl.): 214
50. Marchetti A, Wang L, Magar R, et al. Management of patients with bacilli calmette-guerin-refractory carcinoma in situ of the urinary bladder; cost implications of a clinical trial for valrubicin. Clin Ther 2000; 22 (4): 422-38
51. Rivera I, Wajsman Z. Bladder-sparing treatment of invasive bladder cancer. Cancer Control 2000; 7 (4): 340-6
52. Sternberg CN. Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin Oncol 1996; 23 (5): 621-32
53. Martinez-Pineiro JA, Martinez-Pineiro L. The role of neoadjuvant chemotherapy for invasive bladder cancer. Br J Urol 1998; 82 (1): 33-42
54. von der Maase MH, Hansen SW, Liepa A, et al. Health care resources use for patients with advanced bladder cancer treated with gemcitabine plus cisplatin (GC) versus MVAC in phase III trial [abstract]. Ann Oncol 2000; 11 (4 Suppl.): 74
55. von der Maase MH, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18 (17): 3068-77
56. Bredin HC, Prout Jr GR. One-stage radical cystectomy for bladder carcinoma: operative mortality, cost/benefit analysis. J Urol 1977; 117 (4): 447-51
57. Zenni MK, Griebling TL, Kreder KJ, et al. Impact of preoperative comorbidity on complications and costs in patients undergoing radical cystectomy and orthotopic urinary diversions [abstract]. J Urol 1998; 159 (5 Suppl.): 53
58. Klein FA, Whitmore Jr WF. Bladder papilloma: therapeutic and cost effect of outpatient department management. Urology 1981; 18 (3): 247-9
59. Knoblauch NO, Ronning H, Knudsen P, et al. Routine use of ultrasound and flexible cystoscopy in the control of benign bladder tumours. Int Urol Nephrol 1994; 26 (4): 431-6
60. Hall RR, Parmar MK, Richards AB, et al. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994; 308 (6923): 257-60
61. Kilbridge KL, Kuntz KM, Kagan AR, et al. The cost-effectiveness (CE) of frequent follow-up (F/U) in superficial transitional cell cancer (TCC) of the bladder [abstract]. Am Soc Clin Oncol 1996; 15: 326
62. Nam RK, Redelmeier DA, Spiess PE, et al. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. J Urol 2000; 163 (3): 752-7
63. Lachaine J, Valiquette L, Crott R. Economic evaluation of NMP22 in the management of bladder cancer. Can J Urol 2000; 7 (2): 974-80
64. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002; 167 (1): 75-9
65. The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. The United Kingdom and Eire Bladder Tumour Antigen Study Group. Br J Urol 1997; 79 (3): 362-6
66. Neymark N, Torfs K. Economics of urinary tract cancers: state of the art. Eur Urol 1997; 31 Suppl. 1: 72-81